The significance of interferon gamma inducible protein 16 (IFI16) expression in drug resistant ovarian cancer cell lines
Justyna Borucka(Poznan University of Medical Sciences), Radosław Januchowski(Poznan University of Medical Sciences), Monika Świerczewska(Poznan University of Medical Sciences), Dominika Kaźmierczak(Poznan University of Medical Sciences), M. Zabel(Poznan University of Medical Sciences), Karolina Wojtowicz(Poznan University of Medical Sciences), Karolina Sterzyńska(Poznan University of Medical Sciences), Michał Nowicki(Poznan University of Medical Sciences), Andrzej Klejewski(Poznan University of Medical Sciences), Marta Nowacka(Poznan University of Medical Sciences), Rodryg Ramlau(Poznan University of Medical Sciences)
Cited by 10
Related Papers
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
|Journal of Clinical Oncology|2003|943